Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Inotuzumab Ozogamicin B-Cell Non-Hodgkin Lymphoma	Dana-Farber Cancer Institute	P2	B (62)
Polatuzumab Vedotin B-Cell Non-Hodgkin Lymphoma	Brown University	P2	B (62)
Polatuzumab Vedotin Marginal Zone Lymphoma	University of Washington	P2	B (62)
Trastuzumab Emtansine Advanced Malignant Solid Neoplasm	OHSU Knight Cancer Institute	P2	B (62)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Infiltrating Bladder Urothelial Carcinoma	Fred Hutchinson Cancer Center	P2/3	B (62)
rc48-adc Breast Cancer	Fudan University	P4	B (61)
rc48-adc Colorectal Cancer	Anbogen Therapeutics, Inc.	P4	B (61)
Mirvetuximab Soravtansine Ovarian Cancer	AbbVie	P3	B (61)
Trastuzumab Deruxtecan Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P3	B (61)
Brentuximab Vedotin Extranodal Nasal NK/T Cell Lymphoma	Shanghai Zhongshan Hospital	P2	B (61)
Brentuximab Vedotin Angioimmunoblastic T-Cell Lymphoma	Northwestern University	P2	B (61)
Brentuximab Vedotin Sezary Syndrome	City of Hope Medical Center	P2	B (61)
Polatuzumab Vedotin Follicular Lymphoma	City of Hope Medical Center	P2	B (61)
rc48-adc Extranodal NK/T-cell Lymphoma	Rong Tao	P2	B (61)
Tisotumab Vedotin Non-Small Cell Lung Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	B (61)
Trastuzumab Emtansine Non-Small Cell Lung Carcinoma	Guangzhou Institute of Respiratory Disease	P2	B (61)
Loncastuximab Tesirine B-Cell Non-Hodgkin Lymphoma	University of Birmingham	P2/3	B (61)
Loncastuximab Tesirine Refractory B-Cell Non-Hodgkin Lymphoma	University of Birmingham	P2/3	B (61)
rc48-adc Hodgkin Lymphoma	Xiuhua Sun	P4	B (60)
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 HER2 Positive Breast Carcinoma	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	P3	B (60)
Brentuximab Vedotin Hodgkin'S Lymphoma, Lymphocytic Depletion	National Cancer Institute (NCI)	P3	B (60)
ds-8201a HER2 Positive Breast Carcinoma	Daiichi Sankyo	P3	B (60)
ds-8201a Residual Invasive Breast Cancer	Daiichi Sankyo	P3	B (60)
Ifinatamab Deruxtecan Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P3	B (60)
Immunoglobulin G1 [240-alanine,241-alanine], anti-(human folate receptor ?) (human monoclonal PRO1184 ?1-chain, complex with human monoclonal PRO1184 ?-chain, dimer, 214??,214???,226,226?,232,232?,235,235?-octakis(thioether) with N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide PSOC	Genmab	P3	B (60)

Showing 101 to 125 of 1,027 assets

PreviousPage 5 of 42Next